The Diabetes Complications and Control Trial identified a threefold increase in severe hypoglycemia (SH) as the major risk associated with intensive insulin therapy.1 More recently, survey data from the type 1 diabetes (T1D) exchange showed 6% of individuals with T1D reported experiencing seizure or loss of consciousness due to hypoglycemia in the 3 months before questionnaire completion. The gene discussed is INS; the disease is type 1 diabetes mellitus.